Aflibercept
What is Eylea (Aflibercept)?
Approved To Treat
Related Clinical Trials
Summary: This study is open to adults with diabetic retinopathy. People who have non-proliferative diabetic retinopathy of moderate or high severity can join the study. The purpose of this study is to find out whether a medicine called BI 764524 helps people with diabetic retinopathy. The study also aims to find a suitable treatment plan for BI 764524. Participants are put into 5 groups by chance. Particip...
Summary: Researchers are looking for new ways to treat diabetic macular edema (DME). In this trial, researchers want to learn if a trial medicine called MK-8748 can treat DME. An available standard (usual) treatment for DME is aflibercept. However, standard treatments such as aflibercept may not work for every person. The main goal of this trial is to learn if MK-8748 works as well as aflibercept to treat ...
Summary: Researchers are looking for new ways to treat diabetic macular edema (DME). In this trial, researchers want to learn if a trial medicine called MK-8748 can treat DME. An available standard (usual) treatment for DME is aflibercept. However, standard treatments such as aflibercept may not work for every person. The main goal of this trial is to learn if MK-8748 works as well as aflibercept to treat ...
Related Latest Advances
Brand Information
- Injection: 8 mg (0.07 mL of a 114.3 mg/mL solution) in a single-dose glass vial
- Hypersensitivity
- Endophthalmitis, Retinal Detachments, and Retinal Vasculitis with or without Occlusion
- Increase in intraocular pressure
- Thromboembolic events
- Retinal vasculitis and occlusive retinal vasculitis related to intravitreal injection with aflibercept (reported at a rate of 0.6 and 0.2 per 1 million injections, respectively, based on postmarketing experience from November 2011 until November 2023).
- Scleritis.
- one aflibercept 8 mg/0.07 mL single-dose glass vial
- one 18-gauge × 1½-inch, 5-micron, filter needle for withdrawal
- one 30-gauge × ½-inch injection needle for intravitreal injection
- one 1-mL syringe for administration
- one Prescribing Information

- one aflibercept 8 mg/0.07 mL single-dose glass vial
- one Prescribing Information





